NeuroPhage Pharmaceuticals, a US-based developer of drugs for Alzheimer’s disease, has raised $12.4m in its series B round led by Mérieux Développement, the quasi-corporate venturing unit of France-based holding company Institut Mérieux.

Ireland-based drugs group Shire also participated in the round, while its $7m A round angel investors also reinvested in the company treating plaques (pictured).

Valérie Calenda, partner at Mérieux Développement, which plans to invest €70m ($100m) as a minority shareholder in third parties between 2010 and 2013, will join NeuroPhage’s board and Michael Heartlein, vice-president of research at Shire Human Genetic Therapies, will be a board observer.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?